Skip to main content

RSV Challenge Study (CIR320)

The purpose of this study is to test the safety a live recombinant RSV vaccine, administered using a nasal atomizer.

The study is:

  • 6 months long
  • enrolling healthy adults 18-50 years old
  • at least 2 screening visits
  • an inpatient challenge phase (about 12 days)
  • 2 outpatient follow up visits 
  • 1 follow up phone call

 

Screening Dates

Wednesday, 4/17/2024

Thursday, 4/18/2024

Screening Location

CIR at Bayview Medical Center

301 Building, 4th Floor 

301 Mason Lord Drive

Baltimore, MD 21224

 

Study Period

6 months

Compensation

Up to $4310